It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well ...

Emma Walmsley has also been busy shaking up the company and has replaced 50 top managers, around 40% of the company’s management. Pfizer said in October that it is considering selling its ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers ...

Some health professionals have spoken out about President Donald Trump’s nomination of Robert F. Kennedy, Jr., for Secretary ...

(Bloomberg) -- GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple ...

Two Senate committees are expected to question Robert F. Kennedy Jr. on how his disproven views of science and medicine ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

Starting the year strong at JP Morgan Healthcare conference with some exciting news today - the proposed acquisition of IDRx Inc. aligned to our ambition to address the critical needs of patients ...